Inreda Diabetic
- Company typePrivate
- Founded2005
- HeadquartersGoor, Netherlands
- Headcount—
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
Inreda Diabetic firmographics
Firmographics- Name
- Inreda Diabetic
- Legal name
- Inreda Diabetic B.V.
- Website
- https://inredadiabetic.nl
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Ownership category
- akta.pro rank
Inreda Diabetic industry classification
Industry- Product category
- Diabetes Medical Devices (Artificial Pancreas Systems)
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
- akta.pro secondary industries
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Type 1 Diabetes Care (HLAKADAB)
Keywords
Where Inreda Diabetic is headquartered
LocationHeadquarters
- HQ city
- Goor
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
Inreda Diabetic business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Device and Disposables Sales: The Inreda AP device and associated consumables (sensors, infusion sets, insulin/glucagon cartridges) are provided to patients through project-based arrangements with healthcare insurers. Currently, participation in projects does not involve costs for the device including disposables. Full reimbursement is expected in 2026.
- Project-based Revenue: Revenue generated through structured research projects with health insurers Menzis and CZ enabling patients to use the treatment at home, and the DARE RCT study coordinated by UMC Utrecht.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based access (current) |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels10 records
Inreda Diabetic product offering
Product offeringCore offering
Inreda Diabetic develops, manufactures, and supplies the Inreda AP, a bi-hormonal fully closed loop artificial pancreas system for people with type 1 diabetes. The integrated device combines two continuous glucose sensors, a self-learning algorithm, and dual infusion sets to autonomously administer insulin or glucagon 24/7 without requiring meal or exercise announcements. The company sells the device together with disposables (sensors, infusion sets, cartridges) and adjacent accessories, and delivers clinical training services to healthcare professionals and patients.
Product overview
Inreda Diabetic offers the Inreda AP (Artificial Pancreas), a bi-hormonal fully closed loop system for automated blood glucose regulation in people with type 1 diabetes. The product portfolio includes the AP5 (CE MDR certified, currently in use) and AP6 (under development). The system operates as an all-in-one solution with two glucose sensors, a main device, and two infusion sets that automatically deliver insulin or glucagon based on continuous glucose monitoring. Users do not need to enter carbohydrates or announce meals/exercise. The ecosystem includes wearing accessories (special shirt, belt bag, hip bag) and the MijnInreda online platform for remote care and healthcare professional access. The algorithm is responsive and self-learning, automatically adjusting insulin settings to individual patient needs. The company also provides clinical training services for healthcare professionals and patients.
Differentiator
Problem solved
Functional benefit
Products and services
- Inreda AP5 The CE MDR certified version of the Inreda artificial pancreas, currently in use across multiple Dutch hospital and insurer projects. A bi-hormonal fully closed loop system that automatically regulates blood glucose in adults with type 1 diabetes by administering insulin and glucagon via dual infusion sets based on continuous data from two glucose sensors.
- MijnInreda An online environment for remote care accessible to healthcare professionals and Inreda AP users; enables clinicians to view patient reports, participate in treatment-focused training, and use the platform as an information hub for Inreda AP treatment.
- Inreda AP Special Shirt A specially designed shirt with a pocket to hold the Inreda AP device, intended for comfortable wear during the day and at night, particularly during sleep.
- Inreda AP Belt Bag A belt bag accessory for wearing the Inreda AP device discreetly on the body during daily activities.
- Inreda AP Hip Bag A hip bag accessory for wearing the Inreda AP device during daily activities.
- Clinical Training Services Training and coaching services delivered by Inreda for healthcare professionals (diabetes nurses and internists) and patients on the use and implementation of the Inreda AP system, including onboarding support and ongoing coaching at participating Dutch hospitals.
Quantifiable outcome
- Time In Range improved from 55.5% to 80.3% after 1 year of treatment
- +6 more outcomes
Companies that use Inreda Diabetic
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
Inreda Diabetic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature5 records
Inreda Diabetic partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- UMC UtrechtcoreUMC Utrecht coordinates the DARE Study - a randomized controlled trial on cost-effectiveness of the Inreda AP compared to current treatments. Dutch Healthcare Institute and ZonMw have provided 'Promising Healthcare' funding. 240 individuals participate in this RCT.
- DEKRAcoreDEKRA is the Notified Body that certified Inreda's quality management system (ISO 13485:2012) and issued CE certification for the Inreda AP device under MDR regulations.
- Stichting RobopumpminorFoundation supporting the development of the Inreda AP through fundraising and community advocacy. Provides a way for supporters to contribute financially to the artificial pancreas development for children.
- Diabetes FondsminorDutch Diabetes Foundation is highlighting the Inreda AP project and providing support. Shares same mission as Inreda: better life for people with diabetes, free from worries and fear of complications.
- Stichting DiabestminorOrganization by people with diabetes that organizes annual expeditions and fundraising for Inreda AP development. Raised €4,880.50 for clinical study materials in 2016 and later for device miniaturization.
- Roche Diabetes CarecoreAccu-Chek infusion sets from Roche Diabetes Care are used in the AP system - one for insulin and one for glucagon. The AP system is not compatible with other infusion sets.
- Participating Dutch Hospitals (14+ for Menzis/CZ project)coreHospitals including Canisius Wilhelmina Ziekenhuis Nijmegen, Medisch Spectrum Twente Enschede, Rijnstate Arnhem, Slingeland Doetinchem, Ziekenhuis Gelderse Vallei Ede, ZGT Almelo, Deventer Ziekenhuis, Radboud UMC, Zuyderland Heerlen, ETZ Tilburg, Erasmus MC, Haga Den Haag, Elkerliek Helmond participating in patient treatment projects.
- Participating Dutch Hospitals (12+ for DARE study)coreHospitals including Catharina Eindhoven, Amsterdam UMC VU and AMC, OLVG Amsterdam, Martini Groningen, UMC Groningen, LUMC Leiden, Tergooi Hilversum, Meander Amersfoort, Gelre Apeldoorn, Isala Zwolle, St. Antonius Nieuwegein participating in DARE RCT.
- Amsterdam UMCminorCollaborating with Amsterdam UMC to research effectiveness of the Inreda AP with individuals who have undergone pancreatectomy or pancreatitis, and therefore have type 3c diabetes.
Scale indicators10 records
Recent moves6 records
Expansion highlights3 records
Inreda Diabetic competitors and assessment
Company assessmentDirect peers
- Beta Bionics: Beta Bionics manufactures the iLet, a bi-hormonal (insulin + glucagon) closed-loop system for type 1 diabetes. It is the closest direct competitor to Inreda AP, fighting for the same bi-hormonal clinical positioning and outcomes-based differentiator.
Broad incumbents
- Medtronic: Medtronic offers the MiniMed 780G, a single-hormone hybrid closed-loop system, and supplies the Guardian CGM sensors used in the Inreda AP. It is the dominant incumbent in insulin pump therapy and a key supplier to Inreda.
- Tandem Diabetes Care: Tandem's t:slim X2 with Control-IQ is a leading single-hormone automated insulin delivery system widely used in T1D. Comparable as a competing AID platform targeting the same HCP and patient channels.
- Insulet: Insulet's Omnipod 5 is a tubeless patch pump with built-in AID algorithm. Competes in the same AID category but with patch-pump form factor and single-hormone control, contrasting with Inreda's bi-hormonal approach.
Emerging players
- Diabeloop: Diabeloop develops a closed-loop insulin delivery system (DBLG1) primarily in Europe. Comparable as an algorithm-driven AID player focused on European T1D market, though its system is single-hormone.
- CamDiab: CamDiab provides the CamAPS FX closed-loop algorithm used with various insulin pumps and CGM in Europe. Comparable as an AID software platform addressing the same T1D patient and HCP segments as Inreda.
Others
- Dexcom: Dexcom is a leading CGM manufacturer widely used in AID systems. While Inreda currently uses Medtronic Guardian sensors, Dexcom is the broader CGM supplier that any AID ecosystem interfaces with.
- Abbott Diabetes Care: Abbott's FreeStyle Libre is the world's most widely used CGM. Adjacent to Inreda as a glucose-sensing technology that could be integrated into future generations of the AP.
- Roche Diabetes Care: Roche supplies the Accu-Chek infusion sets used in the Inreda AP for both insulin and glucagon delivery. A critical infrastructure partner and comparable stakeholder in the diabetes care supply chain.
Regional players
- Ypsomed: Ypsomed offers the mylife YpsoPump and an AID ecosystem with CamDiab integration, primarily in European markets. Comparable as an insulin pump and AID platform player operating in the same European HCP channels as Inreda.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Inreda Diabetic social profiles
Digital presenceInreda Diabetic compliance and trust
Trust signalCompliance4 records
Inreda Diabetic financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inreda Diabetic leadership team
Management profileNumber of profiles
Profiles1 record
Inreda Diabetic funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inreda Diabetic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inreda Diabetic
What does Inreda Diabetic do?
Inreda Diabetic develops, manufactures, and supplies the Inreda AP, a bi-hormonal fully closed loop artificial pancreas system for people with type 1 diabetes. The integrated device combines two continuous glucose sensors, a self-learning algorithm, and dual infusion sets to autonomously administer insulin or glucagon 24/7 without requiring meal or exercise announcements. The company sells the device together with disposables (sensors, infusion sets, cartridges) and adjacent accessories, and delivers clinical training services to healthcare professionals and patients.
Is Inreda Diabetic a public or private company?
Inreda Diabetic is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Inreda Diabetic founded?
Inreda Diabetic was founded in 2005.
Where is Inreda Diabetic based?
Inreda Diabetic is headquartered in Goor, Netherlands, in the Europe region.
How does Inreda Diabetic make money?
Two revenue lines are on record. Device and Disposables Sales are the primary driver. The others are project-based Revenue.
Who are Inreda Diabetic's main competitors?
Beta Bionics is listed as a direct peer. Broad incumbents are Medtronic, Tandem Diabetes Care and Insulet. Emerging players are Diabeloop and CamDiab. Others are Dexcom, Abbott Diabetes Care and Roche Diabetes Care. Ypsomed is listed as a regional player.
Does Inreda Diabetic have an API?
No public API is recorded for Inreda Diabetic.
What industry is Inreda Diabetic in?
Inreda Diabetic's product category is Diabetes Medical Devices (Artificial Pancreas Systems). Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 334510 and its SIC code is 3845.